Tata Consultancy Services (TCS) shares jumped over 3% following its Q3 results. Morgan Stanley upgraded the stock to Overweight, while Motilal Oswal and Nuvama reiterated their buy stance. TCS reported higher-than-expected revenue but lower bottomline. Morgan Stanley raised the price target to Rs 4,240. Motilal Oswal has a target of Rs 4,250. Nuvama revised the target to Rs 4,500. Kotak maintained an Add rating.
Dr Reddy’s, Sun Pharma and other pharma stocks fall up to 3% as Trump threatens 25% tariff on India
Indian pharma stocks fell up to 3% after U.S. President Trump announced a 25% tariff on Indian imports over its trade with Russia. Concerns rose